Trials / Not Yet Recruiting
Not Yet RecruitingNCT05540275
Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
Phase 2 Study to Evaluate the Clinical Efficacy and Safety of Tislelizumab Plus Low-dose Bevacizumab in Bevacizumab Refractory Recurrent Glioblastoma With PTEN or TERT Gene Mutations
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Henan Provincial People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the clinical efficacy and safety of Tislelizumab (one anti-PD-1 antibody same as nivolumab approved in China) in combination with bevacizumab in patients with recurrent or progressive glioblastoma (GBM) who have progressed on bevacizumab with or without PTEN or TERT gene mutations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tislelizumab plus Bevacizumab | 200mg Tislelizumab plus 3mg/kg bevacizumab every 3 weeks |
Timeline
- Start date
- 2023-10-05
- Primary completion
- 2024-12-01
- Completion
- 2026-12-01
- First posted
- 2022-09-14
- Last updated
- 2023-10-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05540275. Inclusion in this directory is not an endorsement.